How Wyeth Plans to Make Prevnar a $3 Billion Vaccine

Wyeth's conjugated pneumococcal vaccine continues to break records. The company boldly says there is a lot of growth left, enough to take the product through $3 billion a year and perhaps to $4.5 billion. No vaccine has ever reached those heights. Can Wyeth pull it off?

Cole Werble

Wyeth has been turning some heads lately in the investment community. The company’s executive team continues to pound home a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Platform Technologies

More from Advanced Technologies